Literature DB >> 15019927

Hilar cholangiocarcinoma.

Bryan Clary1, William Jarnigan, Henry Pitt, Gregory Gores, Ronald Busuttil, Theodore Pappas.   

Abstract

Cancer of the biliary tree, including those occurring at the major biliary bifurcation (Klatskin's tumor), is an uncommon malignancy. Meaningful experience with these tumors has been limited to a few centers. Recent reports with increasing numbers of patients have allowed the construction of rational approaches to these patients. It is clear from these reports that complete resection with negative histologic margins is the only treatment that offers the possibility of long-term survival. Complete resection of hilar cholangiocarcinomas remains a technically demanding procedure requiring expertise in biliary and hepatic surgery. Patients with unresectable disease constitute a distinct majority and have traditionally been very difficult to successfully palliate and impossible to cure. A panel of hepatobiliary surgeons experienced in the management of hilar cholangiocarcinoma presented a symposium on issues relating to these patients at the recent joint American Hepato-Pancreato-Biliary Association/American Association for the Study of Liver Diseases (AHPBA-AASLD) forum in Boston, MA. The report below offers a summarization of the main points and comments raised by this panel. These summarizations are not meant as an exhaustive review and primarily reflect the opinions of the speakers based upon their experiences and interpretation of the existing literature.

Entities:  

Mesh:

Year:  2004        PMID: 15019927     DOI: 10.1016/j.gassur.2003.12.004

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  6 in total

1.  Addition of hepatectomy decreases liver recurrence and leads to long survival in hilar cholangiocarcinoma.

Authors:  Zheng Shi; Ming-Zhi Yang; Qing-Liang He; Rong-Wen Ou; You-Ting Chen
Journal:  World J Gastroenterol       Date:  2009-04-21       Impact factor: 5.742

2.  Obstructive jaundice due to autoimmune cholangiopathy.

Authors:  Osama Naji; Abdulzahra Hussain; Dennis Baker; Naji Habib; Shamsi El-Hasani
Journal:  BMJ Case Rep       Date:  2009-06-09

3.  Clinical analysis of cholangiocarcinoma patients receiving adjuvant radiotherapy.

Authors:  Danupon Nantajit; Pornwaree Trirussapanich; Sunanta Rojwatkarnjana; Kamonwan Soonklang; Poompis Pattaranutraporn; Kanyanee Laebua; Sasikarn Chamchod
Journal:  Mol Clin Oncol       Date:  2016-11-02

Review 4.  PET-CT in Clinical Adult Oncology: III. Gastrointestinal Malignancies.

Authors:  Bhasker R Koppula; Gabriel C Fine; Ahmed Ebada Salem; Matthew F Covington; Richard H Wiggins; John M Hoffman; Kathryn A Morton
Journal:  Cancers (Basel)       Date:  2022-05-27       Impact factor: 6.575

5.  Outcome of surgical resection in Klatskin tumors.

Authors:  Alejandro Serrablo; Luis Tejedor
Journal:  World J Gastrointest Oncol       Date:  2013-07-15

6.  Percutaneous Y-shape reconstructive biliary stenting in Klatskin cholangiocarcinoma through a single left-sided entry.

Authors:  Ghazi Adlan Alshumrani; Abdullah Murhaf Al-Khani
Journal:  Ann Saudi Med       Date:  2022-02-03       Impact factor: 1.526

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.